Enteropeptidase inhibition improves kidney function in a rat model of diabetic kidney disease.


Journal

Diabetes, obesity & metabolism
ISSN: 1463-1326
Titre abrégé: Diabetes Obes Metab
Pays: England
ID NLM: 100883645

Informations de publication

Date de publication:
01 2021
Historique:
received: 10 06 2020
revised: 10 08 2020
accepted: 31 08 2020
pubmed: 8 9 2020
medline: 6 7 2021
entrez: 7 9 2020
Statut: ppublish

Résumé

To examine the effects of an enteropeptidase inhibitor, SCO-792, on kidney function in rats. The pharmacological effects of SCO-792 were evaluated in Wistar fatty (WF) rats, a rat model of diabetic kidney disease (DKD). Oral administration of SCO-792 increased faecal protein content and improved glycaemic control in WF rats. SCO-792 elicited a rapid decrease in urine albumin-to-creatinine ratio (UACR). SCO-792 also normalized glomerular hyperfiltration and decreased fibrosis, inflammation and tubular injury markers in the kidneys. However, pioglitazone-induced glycaemic improvement had no effect on kidney variables. Dietary supplementation of amino acids (AAs), which bypass the action of enteropeptidase inhibition, mitigated the effect of SCO-792 on UACR reduction, suggesting a pivotal role for enteropeptidase. Furthermore, autophagy activity in the glomerulus, which is impaired in DKD, was elevated in SCO-792-treated rats. Finally, a therapeutically additive effect on UACR reduction was observed with a combination of SCO-792 with irbesartan, an angiotensin II receptor blocker. This study is the first to demonstrate that enteropeptidase inhibition is effective in improving disease conditions in DKD. SCO-792-induced therapeutic efficacy is likely to be independent of glycaemic control and mediated by the regulation of AAs and autophagy. Taken together with a combination effect of irbesartan, SCO-792 may be a novel therapeutic option for patients with DKD.

Identifiants

pubmed: 32893449
doi: 10.1111/dom.14190
pmc: PMC7756647
doi:

Substances chimiques

Enteropeptidase EC 3.4.21.9

Types de publication

Journal Article Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

86-96

Informations de copyright

© 2020 The Authors. Diabetes, Obesity and Metabolism published by John Wiley & Sons Ltd.

Références

PLoS One. 2016 Dec 16;11(12):e0168396
pubmed: 27992511
Lancet. 2019 Jan 5;393(10166):31-39
pubmed: 30424892
Kidney Int. 1992 Oct;42(4):1006-11
pubmed: 1453577
Cell Mol Biol Lett. 2016 Dec 13;21:29
pubmed: 28536631
Am J Physiol Renal Physiol. 2015 Jul 1;309(1):F2-23
pubmed: 25925260
J Vis Exp. 2018 Nov 1;(141):
pubmed: 30451231
Curr Opin Clin Nutr Metab Care. 2017 Jan;20(1):77-85
pubmed: 27801685
Diabetes. 2015 May;64(5):1555-63
pubmed: 25475435
Am J Physiol Regul Integr Comp Physiol. 2011 May;300(5):R1009-22
pubmed: 21228342
Am J Physiol. 1994 Nov;267(5 Pt 2):F703-8
pubmed: 7977774
Clin J Am Soc Nephrol. 2017 Aug 7;12(8):1366-1373
pubmed: 28280116
J Cell Sci. 2004 Jun 1;117(Pt 13):2805-12
pubmed: 15169837
Diabetes. 1981 Dec;30(12):1045-50
pubmed: 7030830
Front Biosci (Elite Ed). 2009 Jun 01;1:242-9
pubmed: 19482641
Diabetes. 2017 Feb;66(2):235-240
pubmed: 28108603
Kidney Int. 2016 Nov;90(5):950-964
pubmed: 27325184
Diabetes Obes Metab. 2021 Jan;23(1):86-96
pubmed: 32893449
Pharmacol Res Perspect. 2019 Sep 04;7(5):e00517
pubmed: 31508234
Proc Soc Exp Biol Med. 1994 Jun;206(2):114-8
pubmed: 8208733
Kidney Int Rep. 2017 Aug 30;3(1):105-114
pubmed: 29340320
J Am Soc Nephrol. 2013 Feb;24(2):198-207
pubmed: 23291473
N Engl J Med. 2019 Jun 13;380(24):2295-2306
pubmed: 30990260
J Clin Invest. 2010 Apr;120(4):1084-96
pubmed: 20200449
Eur J Pharmacol. 2016 Nov 15;791:8-24
pubmed: 27568833
Hypertens Res. 2003 Apr;26(4):339-47
pubmed: 12733703
Nat Rev Nephrol. 2018 Jul;14(7):442-456
pubmed: 29760448
Diabetes Obes Metab. 2019 Oct;21(10):2228-2239
pubmed: 31144422
J Proteome Res. 2014 Jul 3;13(7):3455-66
pubmed: 24933025
Am J Physiol Renal Physiol. 2008 Apr;294(4):F697-701
pubmed: 18272603
Diabetes Metab Syndr. 2017 Nov;11 Suppl 1:S133-S139
pubmed: 27993541
Nephrol Dial Transplant. 2015 Jan;30(1):6-8
pubmed: 25358494
Kidney Int. 1992 Nov;42(5):1207-16
pubmed: 1453605
Amino Acids. 2015 Oct;47(10):2065-88
pubmed: 24965527
Cardiovasc Drugs Ther. 2017 Dec;31(5-6):579-592
pubmed: 28956186
Am J Nephrol. 2011;34(3):268-80
pubmed: 21822010
Nat Commun. 2020 Jun 19;11(1):3148
pubmed: 32561715
Nutrients. 2018 Apr 27;10(5):
pubmed: 29702558
Trends Biochem Sci. 1989 Mar;14(3):110-2
pubmed: 2658218
Curr Opin Pharmacol. 2017 Apr;33:34-40
pubmed: 28482281

Auteurs

Jun Sugama (J)

SCOHIA PHARMA, Inc., Fujisawa, Japan.

Yuko Katayama (Y)

SCOHIA PHARMA, Inc., Fujisawa, Japan.

Yusuke Moritoh (Y)

SCOHIA PHARMA, Inc., Fujisawa, Japan.

Masanori Watanabe (M)

SCOHIA PHARMA, Inc., Fujisawa, Japan.

Articles similaires

Robotic Surgical Procedures Animals Humans Telemedicine Models, Animal

Odour generalisation and detection dog training.

Lyn Caldicott, Thomas W Pike, Helen E Zulch et al.
1.00
Animals Odorants Dogs Generalization, Psychological Smell
Animals TOR Serine-Threonine Kinases Colorectal Neoplasms Colitis Mice
Animals Tail Swine Behavior, Animal Animal Husbandry

Classifications MeSH